Trilaciclib
Trilaciclib is a first-in-class CDK4/6 inhibitor that transiently arrests hematopoietic stem and progenitor cells in G1 phase before chemotherapy administration, thereby protecting bone marrow from chemotherapy-induced damage. It is used to decrease the incidence of chemotherapy-induced myelosuppression in adults receiving certain chemotherapy regimens for small cell lung cancer. Its myeloprotective mechanism distinguishes it from CDK4/6 inhibitors used as antineoplastic agents.
Masse moléculaire
446,5000 g/mol
LogP
2,60
TPSA
91,20 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Mécanisme d'action
Selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma protein and arresting the cell cycle at the G1/S transition to prevent cancer cell proliferation.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma protein and arresting the cell cycle at the G1/S transition to prevent cancer cell proliferation.
Structure 2D
Cite this structure
Embed this structure
SMILES
CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1
InChI
InChI=1S/C24H30N8O/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29)
Molecular Formula
C24H30N8O
HBD / HBA
2 / 7
Liaisons Rotatives
3
Atomes Lourds
33
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
Trilaciclib is a first-in-class CDK4/6 inhibitor that transiently arrests hematopoietic stem and progenitor cells in G1 phase before chemotherapy administration, thereby protecting bone marrow from chemotherapy-induced damage. It is used to decrease the incidence of chemotherapy-induced myelosuppression in adults receiving certain chemotherapy regimens for small cell lung cancer. Its myeloprotective mechanism distinguishes it from CDK4/6 inhibitors used as antineoplastic agents.
Selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma protein and arresting the cell cycle at the G1/S transition to prevent cancer cell proliferation.
Yes, Trilaciclib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3894860. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 68029831. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="trilaciclib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/trilaciclib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/trilaciclib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/trilaciclib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="trilaciclib"></drugfyi-drug>